Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has established a licensing and commercialization agreement with a ...

The Food and Drug Administration has approved Fresenius Kabi's Biologics License Application for the denosumab biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht). These denosumab ...

Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE ®1), a biosimilar to Prolia 2 (denosumab) across patient subgroups compared to the reference ...

Treatment of osteoporosis with denosumab, compared with bisphosphonate therapy, may help prevent progression to type 2 diabetes (T2D) in those at high risk for it. In patients with osteoporosis who ...

THOUSAND OAKS, Calif., May 8, 2023 /PRNewswire/ -- Amgen (AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare ...

Biocon launches two FDA-approved interchangeable denosumab biosimilars in the US, targeting osteoporosis and bone metastasis in a $5B market.

Xgeva and Prolia are two drugs Amgen investors need to keep an eye on. Thanks to label expansion that permitted wider use of the drugs, they've been Amgen's fastest-growing products this past year.